GSK said on Friday a panel ‍of the European Medicines Agency had backed the use of its ‌respiratory syncytial ‌virus (RSV) ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

In the third quarter, our revenue were $1 billion, driven by sales of our fully approved vaccines, Spikevax, mNEXSPIKE, ...

Last month marked a major turning point as Google launched Gemini 3 [1], proving that new AI models can now outperform humans on critical tasks. At the same time, global regulators accelerated the ...

Merck MRK is going to face a major patent cliff, as its blockbuster PD-L1 therapy Keytruda is nearing loss of exclusivity ...

Annual Meeting 2025 Highlights" report has been added to ResearchAndMarkets.com's offering. IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare ...

Research led by the Veterans Affairs Portland Health Care System in Portland, Oregon, found that a single dose of respiratory ...

Emerging market opportunities include advanced therapies for RSV, COVID-19, UTIs, HIV, and fungal infections, with promising candidates such as Moderna's mRNA assets, GSK's TBP-PI-HBr, and Armata's AP ...

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...